The aim of this investigation was to spotlight the utility of nuclear magnetic resonance (NMR) as a multi-attribute methodology for the characterization of therapeutic antibodies. On this case examine, we in contrast outcomes from isothermal chemical denaturation (ICD) and NMR with commonplace strategies to narrate conformational states of a mannequin monoclonal antibody (mAb1) with protein-protein interactions (PPI) that result in self – affiliation in concentrated options.
The rise in aggregation fee and relative viscosity for mAb1 was discovered to be each focus and pH dependent. The free vitality of unfolding (∆G⁰) from ICD and thermal evaluation in dilute options indicated that though the native state predominated between pH 4 – pH 7, it was disrupted on the CH2 and unfolded noncooperatively underneath acidic situations.
One-dimensional (1D) 1H NMR and two-dimensional (2D) 13C-1H NMR carried out, in concentrated options, confirmed that PPI between pH 4 – 7 occurred whereas mAb1 was within the native state. NMR corroborated that mAb1 maintained a dominant native state at formulation-relevant situations on the examined pH vary, had elevated world molecular tumbling dynamics at decrease pH and confirmed elevated PPI at larger pH situations.
This report aligns and compares typical characterization of an IgG1 with evaluation of construction by NMR and supplied a extra exact evaluation and deeper perception into the conformation of an IgG1 in concentrated options.
Elevated mycobacterium avium subsp. paratuberculosis (MAP) antibody titer in Japanese a number of sclerosis
To research whether or not antibody manufacturing in opposition to mycobacterium avium subsp. paratuberculosis (MAP) is said to scientific traits of a number of sclerosis (MS) and human leukocyte antigen (HLA) alleles, IgG antibody in opposition to three MAP peptides and two human peptides homologous to MAP had been measured in sera from 103 MS sufferers and 50 wholesome controls (HCs).
MS sufferers had larger IgG ranges in opposition to MAP2694295-303 (MAP2694-IgG) than HCs, whereas the opposite antibodies had been comparable. Multivariate evaluation demonstrated that larger MAP2694-IgG titers had been related to larger EDSS scores, however not with HLA alleles or dairy product consumption. Immune response in opposition to MAP could worsen MS incapacity.
Predominant mesangial IgM, C3, and λ gentle chain depositions and interstitial nephritis in a affected person with overlap syndrome and positivity for anti-mitochondrial M2 antibody: a case report
Overlap syndrome refers to a gaggle of situations which have scientific options of a couple of well-characterised rheumatic illness and meet the respective classification standards. There aren’t any typical renal histological findings in overlap syndrome. When sufferers with overlap syndrome develop renal dysfunction, varied potential causes, together with lupus nephritis (LN), renal disaster by systemic sclerosis, interstitial nephritis, and so forth, should be distinguished.
Right here, we report a 44-year-old lady with overlap syndrome involving systemic lupus erythematosus (SLE), diffuse cutaneous systemic scleroderma, and Sjogren’s syndrome, who was additionally optimistic for anti-mitochondrial M2 antibody. She developed glomerular haematuria, proteinuria, and enhance in creatinine appeared regularly.
Suspecting LN, renal biopsy was carried out. Nonetheless, within the interstitium, gentle infiltration of lymphocytes and plasma cells and really partial fibrosis had been noticed. Immunofluorescence microscopy revealed predominant mesangial immunoglobulin M, C3, and λ gentle chain staining. General, LN was not recognized primarily based on these findings.
Renal dysfunction was normalised by glucocorticoid remedy for three months. This case suggests the significance of a renal analysis primarily based on renal pathological findings, particularly in a case of overlap syndrome together with SLE.
A Japanese Affected person with Anti-PM/Scl and Centromere Antibody-Constructive Scleroderma-Amyopathic Dermatomyositis Overlap Syndrome Who Developed Renal Disaster
Anti-PM/Scl antibodies are related to the overlap syndrome of systemic sclerosis and dermatomyositis/polymyositis (SSc-DM/PM), and are present in 50% of SSc-DM/PM instances in Europe and the USA, whereas they’re uncommon in Japan. We report a case of an 80-year-old Japanese feminine with SSc-amyopathic dermatomyositis (ADM) overlap syndrome, who developed scleroderma renal disaster (SRC), a complication of SSc.
She had optimistic antinuclear antibodies in a discrete-speckled and nucleolar sample and anticentromere antibodies and anti-PM/Scl antibodies had been confirmed by ELISA and immunoprecipitation, respectively. The incidence fee of SRC in SSc sufferers varies considerably relying on the specificity of autoantibodies, with the very best incidence of ~50% in anti-RNA polymerase III antibody optimistic sufferers, adopted by ~10% in anti-PM/Scl and decrease incidence of 0.45% in anticentromere antibody-positive instances.
Anti-PM/Scl antibodies are unusual in Japanese sufferers presumably because of its robust affiliation with sure HLA haplotype that’s uncommon in Japanese. Scientific significance of anti-PM/Scl antibodies in Japanese sufferers will should be clarified with accumulation of instances in future research.
Intrinsic physicochemical profile of marketed antibody-based biotherapeutics
Feeding biopharma pipelines with biotherapeutic candidates that possess fascinating developability profiles will help enhance the productiveness of biologic drug discovery and improvement. Right here, we’ve got derived an in silico profile by analyzing computed physicochemical descriptors for the variable areas (Fv) present in 77 marketed antibody-based biotherapeutics. Fv areas of those biotherapeutics show vital diversities of their germlines, complementarity figuring out area loop lengths, hydrophobicity, and cost distributions.
Moreover, an evaluation of 24 physicochemical descriptors, calculated utilizing homology-based molecular fashions, has yielded 5 nonredundant descriptors whose distributions symbolize stability, isoelectric level, and molecular floor traits of their Fv areas. Fv areas of candidates from our inner discovery campaigns, human next-generation sequencing repertoires, and people in clinical-stages (CST) had been assessed for similarity with the physicochemical profile derived right here.
The Fv areas in 33% of CST antibodies present physicochemical properties which are dissimilar to presently marketed biotherapeutics. As compared, physicochemical traits of ∼29% of the Fv areas in human antibodies and ∼27% of our inner hits deviated considerably from these of marketed biotherapeutics.
CD146 Antibody |
49868-100ul |
SAB |
100ul |
EUR 333 |
CD146 Antibody |
49868-50ul |
SAB |
50ul |
EUR 239 |
CD146 Antibody |
20-abx242914 |
Abbexa |
|
|
|
anti-CD146 |
YF-PA13077 |
Abfrontier |
50 ug |
EUR 363 |
Description: Mouse polyclonal to CD146 |
CD146 antibody |
10R-6489 |
Fitzgerald |
100 ug |
EUR 208 |
Description: Mouse monoclonal CD146 antibody |
CD146 antibody |
70R-14273 |
Fitzgerald |
100 ug |
EUR 322 |
Description: Affinity purified Mouse polyclonal CD146 antibody |
Anti-CD146 antibody |
STJ190008 |
St John's Laboratory |
200 µl |
EUR 197 |
Description: Unconjugated Mouse monoclonal to CD146 (AS1A31) |
CD146 Antibody (FITC) |
abx200496-100tests |
Abbexa |
100 tests |
EUR 398 |
|
CD146 Antibody (Biotin) |
abx200500-100ug |
Abbexa |
100 ug |
EUR 384 |
|
MCAM(CD146) Antibody |
48005-100ul |
SAB |
100ul |
EUR 333 |
MCAM(CD146) Antibody |
48005-50ul |
SAB |
50ul |
EUR 239 |
CD146 Conjugated Antibody |
C49868 |
SAB |
100ul |
EUR 397 |
CD146 antibody (biotin) |
61R-CD146aHUBT |
Fitzgerald |
100 tests |
EUR 521 |
Description: Mouse monoclonal CD146 antibody (biotin) |
Anti-CD146/MCAM Antibody |
RP1050 |
BosterBio |
100ug/vial |
EUR 334 |
Anti-CD146/MCAM Antibody |
PA1736 |
BosterBio |
100ug/vial |
EUR 334 |
Anti-Hu CD146 Purified |
11-783-C025 |
ExBio |
0.025 mg |
EUR 99 |
Anti-Hu CD146 Purified |
11-783-C100 |
ExBio |
0.1 mg |
EUR 158 |
Anti-Hu CD146 PE |
1P-783-T025 |
ExBio |
25 tests |
EUR 140 |
Anti-Hu CD146 PE |
1P-783-T100 |
ExBio |
100 tests |
EUR 240 |
CD146 Monoclonal Antibody [RMC563A] |
A68401 |
EpiGentek |
100 µl |
EUR 628.55 |
Description: fast delivery possible |
anti- CD146/MCAM antibody |
FNab01428 |
FN Test |
100µg |
EUR 505.25 |
|
Description: Antibody raised against CD146/MCAM |
anti- CD146/MCAM antibody |
FNab01429 |
FN Test |
100µg |
EUR 585 |
|
Description: Antibody raised against CD146/MCAM |
MCAM(CD146) Conjugated Antibody |
C48005 |
SAB |
100ul |
EUR 397 |
CD146 recombinant monoclonal antibody |
A5098 |
Bimake |
100ul X 3 |
EUR 595 |
|
Description: A recombinant monoclonal antibody from rabbit against human CD146 for WB, IF,ELISA |
CD146/MCAM Antibody (CT) |
6801-100 |
Biovision |
|
EUR 316 |
Recombinant Human CD146/MCAM Protein |
RP00101 |
Abclonal |
20 μg |
EUR 374 |
Anti-CD146 Rabbit Monoclonal Antibody |
M01683-1 |
BosterBio |
100ug/vial |
EUR 397 |
Description: Rabbit Monoclonal CD146 Antibody. Validated in IP, IF, IHC, WB and tested in Human, Mouse, Rat. |
Polyclonal CD146/MCAM Antibody (CT) |
APR00368G |
Leading Biology |
0.1ml |
EUR 484 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human CD146/MCAM (CT). This antibody is tested and proven to work in the following applications: |
Anti-CD146 Rabbit Monoclonal Antibody |
A1122-50 |
Biovision |
|
EUR 359 |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNC040676-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF405S conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNC040676-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF405S conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNC470676-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF647 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNC470676-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF647 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNCAP0676-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNCAP0676-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNCB0676-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), Biotin conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNCB0676-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), Biotin conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNC810676-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF680R conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNC810676-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF680R conjugate, Concentration: 0.1mg/mL |
Cell Surface Glycoprotein MUC18 (CD146) Antibody |
abx139732-01mg |
Abbexa |
0.1 mg |
EUR 356 |
|
Cell Surface Glycoprotein MUC18 (CD146) Antibody |
abx019043-100ug |
Abbexa |
100 ug |
EUR 342 |
|
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNC700676-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF770 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNC700676-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF770 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNC880676-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF488A conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNC880676-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF488A conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNC940676-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF594 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNC940676-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF594 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNC610676-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF660R conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNC610676-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF660R conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNC680676-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF568 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNC680676-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF568 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNCA0676-250 |
Biotium |
250uL |
EUR 383 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), APC conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNUM0676-50 |
Biotium |
50uL |
EUR 395 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), 1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNCP0676-250 |
Biotium |
250uL |
EUR 383 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), PerCP conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNC050676-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF405M conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNC050676-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF405M conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNC400676-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF640R conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNC400676-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF640R conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNCR0676-250 |
Biotium |
250uL |
EUR 383 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), RPE conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNUB0676-100 |
Biotium |
100uL |
EUR 209 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), Concentration: 0.2mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNUB0676-500 |
Biotium |
500uL |
EUR 458 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), Concentration: 0.2mg/mL |
Cell Surface Glycoprotein MUC18 (CD146) Antibody |
abx413746-02mg |
Abbexa |
0.2 mg |
EUR 565 |
|
Cell Surface Glycoprotein MUC18 (CD146) Antibody |
abx413749-25ug |
Abbexa |
25 ug |
EUR 272 |
|
Cell Surface Glycoprotein MUC18 (CD146) Antibody |
abx413750-1mg |
Abbexa |
1 mg |
EUR 829 |
|
Cell Surface Glycoprotein MUC18 (CD146) Antibody |
abx200495-100ug |
Abbexa |
100 ug |
EUR 328 |
|
Cell Surface Glycoprotein MUC18 (CD146) Antibody |
20-abx225287 |
Abbexa |
-
EUR 370.00
-
EUR 606.00
-
EUR 314.00
|
|
|
Cell Surface Glycoprotein MUC18 (CD146) Antibody |
abx231428-100ug |
Abbexa |
100 ug |
EUR 481 |
|
Cell Surface Glycoprotein MUC18 (CD146) Antibody |
abx231429-100ug |
Abbexa |
100 ug |
EUR 551 |
|
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNC430676-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF543 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNC430676-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF543 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNCH0676-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNCH0676-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNC550676-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF555 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNC550676-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF555 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNC800676-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF680 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
BNC800676-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF680 conjugate, Concentration: 0.1mg/mL |
Anti-CD146 Rabbit Monoclonal Antibody, Clone#RM249 |
M01683-2 |
BosterBio |
100ul |
EUR 375 |
Description: Anti-CD146 Rabbit Monoclonal Antibody, Clone#RM249 tested in WB, IHC, reactive to Human, (Mouse, Rat) |
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
BNC041130-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), CF405S conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
BNC041130-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), CF405S conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
BNC471130-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), CF647 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
BNC471130-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), CF647 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
BNCAP1130-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
BNCAP1130-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
BNC811130-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), CF680R conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
BNC811130-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), CF680R conjugate, Concentration: 0.1mg/mL |
Cell Surface Glycoprotein MUC18 (CD146) Antibody (PE) |
abx139733-100tests |
Abbexa |
100 tests |
EUR 481 |
|
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
BNC681130-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), CF568 conjugate, Concentration: 0.1mg/mL |
The early availability of this data will help information hit choice, lead identification, and optimization of biotherapeutic candidates. Insights from this work can even assist help portfolio threat evaluation, in-licensing, and biopharma collaborations.